 Home > Active Ingredient News > Antitumor Therapy > The treatment of early triple-negative breast cancer blockbuster PD-1 inhibitors reached dual phase 3 clinical...

The treatment of early triple-negative breast cancer blockbuster PD-1 inhibitors reached dual phase 3 clinical...

 Last Update: 2021-05-23
 Source: Internet
 Author: User

Tags

5 20 oil

cancer cell growth

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On May 13, Merck & Co.

TNBC patients account for 15-20% of breast cancer patients, and it is more common in women under the age of 40.

Keytruda is an anti-PD-1 therapy, which increases the body's immune system's ability to detect and fight tumor cells by blocking the immunosuppressive signal mediated by PD-1.

Previously, Merck had reported that this trial reached the primary clinical endpoint of pathological complete remission (pCR, defined as no aggressive residual cancer found in the breast and nearby lymph node tissue after surgery).

Note: The original text has been deleted

▽ attention [drug Mingkang Germany ] micro-channel public number

[Medical attention Mingkang Germany ] ] micro-channel public number

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express | Treatment of early-stage triple-negative breast cancer patients, blockbuster PD-1 inhibitors reach dual phase 3 clinical endpoints

05-21

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

The treatment of early triple-negative breast cancer blockbuster PD-1 inhibitors reached dual phase 3 clinical...

Related Articles

Express | Treatment of early-stage triple-negative breast cancer patients, blockbuster PD-1 inhibitors reach dual phase 3 clinical endpoints